Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
Trial details
- Registry ID
- NCT04723537
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 DiseaseNCT04723537 | RedHill Biopharma Limited | Phase 2, Phase 3 | Terminated | 2021-12-28Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |